VVOS (Vivos Therapeutics Inc.) רווחיות מכירות לפי רווח גולמי

Vivos Therapeutics (VVOS) resilience is based on an apnea therapy platform with strong pricing power and stable FCF. Changes in gross margin confirm this efficiency, where 50.40 serves as the current parameter value. Innovative devices expand airways, creating a new market niche. Meanwhile, the company complies with environmental regulations by optimizing packaging and plastic disposal on clean assembly lines.
פילוחי מדדים מקיפים ואנליטיקה עבור Vivos Therapeutics (VVOS)

Gross margin determines production efficiency by measuring the portion of revenue remaining after covering direct costs of product creation. By analyzing the gross profit level within revenue, an investor assesses the ability of Vivos Therapeutics (VVOS) to scale its innovative dental devices for sleep apnea treatment while maintaining high profitability during the expansion of alternative non-CPAP therapy methods.